
Imran Alibhai, CEO of Tvardi, stated, “We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| TVRD | Tvardi Therapeutics | 1.18 | -2.85 | -70.72% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.18 | -70.72% |

Imran Alibhai, CEO of Tvardi, stated, “We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we

Tvardi Therapeutics Inc. (TVRD) is scheduled to report 3rd quarter earnings on 11/12/2026. Regarding Q3 estimates, Wall Street analysts expect Tvardi Therapeutics Inc. to post earnings of -$0.57 per share.

Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Tvardi Therapeutics, with a price target of $10.00. Debanjana Chatterjee’s rating is based on the potential for TTI-109 to provide

Chardan analyst Gautam Chukka initiated coverage of Tvardi Therapeutics (TVRD) with a Buy rating and $8 price target The firm says Tvardi is a clinical stage biotech developing oral, direct

Tvardi Therapeutics (TVRD) announced the publication of preclinical data evaluating Tvardi’s STAT3 inhibitor in the International Journal of Molecular Sciences. The publication provides additional evidence supporting further investigation of STAT3

Lucid Capital assumed coverage of Tvardi Therapeutics (TVRD) with a Buy rating and price target of $14, up from $6. The company’s first-generation molecule, TTI-101, provided early validation of the

Analyst Sara Nik of H.C. Wainwright maintained a Buy rating on Tvardi Therapeutics, retaining the price target of $9.00. Sara Nik has given his Buy rating due to a combination

Analyst Julian Harrison from BTIG maintained a Buy rating on Tvardi Therapeutics and decreased the price target to $5.00 from $15.00. Julian Harrison has given his Buy rating due to

Imran Alibhai, Chief Executive Officer of Tvardi, stated, “Since our last quarterly report, we have made significant progress in the clinical development of our STAT3 inhibitors. Regarding our next-generation STAT3

In a report released today, Sara Nik from H.C. Wainwright maintained a Buy rating on Tvardi Therapeutics, with a price target of $9.00. Sara Nik has given his Buy rating
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 8, 2026 | ||||
| buy | Initiated | Oct 20, 2026 | ||||
| buy | Initiated | Sep 8, 2026 | ||||
| sell | Reiterated | Aug 20, 2026 | ||||
| buy | Reiterated | Aug 19, 2026 | ||||
| buy | Upgraded | Jul 8, 2026 | ||||
| buy | Upgraded | Jul 8, 2026 | ||||
| buy | Reiterated | May 11, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 6, 2027TBA | $15.74M | $-0.44 | $0.00 | 0.02 | -0.42 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.